The Medical Letter on Drugs and Therapeutics
Lumateperone (Caplyta) for Schizophrenia
July 27, 2020 (Issue: 1603)The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA...more
- Drugs for psychotic disorders. Med Lett Drugs Ther 2016; 58:160.
- SC Fang et al. The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia. Hum Psychopharmacol 2020; 35:e2729.
- J Greenwood et al. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother 2020 June 26 (epub).
- JA Lieberman et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry 2016; 79:952.
- CU Correll et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2020; 77:349.
- FDA Multi-Discipline Review. Available at: https://bit.ly/3gXPNzZ. Accessed July 16, 2020.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.